Data from another meta-analysis revealed that in the randomized, controlled trials (including sitagliptin, saxagliptin and alogliptin) the risk of HF in patients using DPP-4 inhibitors was 24 % [68]. This evidence concerns the gene DPP4 and hydrops fetalis.